Frederick M. Hudson - 02 Nov 2026 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Reporting relationship: Director
Issuer ticker: SUPN
Reported as of: 02 Nov 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Nov 2026, 16:24:54 UTC
Prior SEC filing: 16 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Timothy C. Dec, as attorney-in-fact

Filing notes and source

Key filing fact

Frederick M. Hudson filed Form 4 for SUPERNUS PHARMACEUTICALS, INC. (SUPN) on 04 Nov 2026.

Key facts

This page summarizes Frederick M. Hudson's Form 4 filing for SUPERNUS PHARMACEUTICALS, INC. (SUPN).
13 reported transactions and 12 derivative rows are listed below.
Accepted by SEC: 04 Nov 2026, 16:24.

Change

Previous filing in this sequence was filed on 16 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001438462 Primary reporting owner

Hudson Frederick M.

Relationship: Director
Address: C/O SUPERNUS PHARMACEUTICALS, INC.,, 9715 KEY WEST AVENUE, ROCKVILLE
Signature: /s/ Timothy C. Dec, as attorney-in-fact
Signature date: 04 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SUPN transaction

Common Stock

Other

Transaction value
Shares: -60,413
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SUPN transaction Derivative

Restricted Stock Unit

Other

Transaction value
Shares: -2,989
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,989
Exercise price
Footnotes: F2, F3, F4

SUPN transaction Derivative

Director Stock Option (Right to Buy)

Other

Transaction value
Shares: -7,905
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,905
Exercise price: $25.30
Footnotes: F3

SUPN transaction Derivative

Director Stock Option (Right to Buy)

Other

Transaction value
Shares: -6,036
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,036
Exercise price: $38.60
Footnotes: F3

SUPN transaction Derivative

Director Stock Option (Right to Buy)

Other

Transaction value
Shares: -8,613
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,613
Exercise price: $39.40
Footnotes: F3

SUPN transaction Derivative

Director Stock Option (Right to Buy)

Other

Transaction value
Shares: -12,427
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,427
Exercise price: $36.75
Footnotes: F3

SUPN transaction Derivative

Director Stock Option (Right to Buy)

Other

Transaction value
Shares: -9,305
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,305
Exercise price: $23.99
Footnotes: F3

SUPN transaction Derivative

Director Stock Option (Right to Buy)

Other

Transaction value
Shares: -7,365
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,365
Exercise price: $29.61
Footnotes: F3

SUPN transaction Derivative

Director Stock Option (Right to Buy)

Other

Transaction value
Shares: -6,847
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,847
Exercise price: $32.20
Footnotes: F3

SUPN transaction Derivative

Director Stock Option (Right to Buy)

Other

Transaction value
Shares: -6,293
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,293
Exercise price: $38.60
Footnotes: F3, F5

SUPN transaction Derivative

Director Stock Option (Right to Buy)

Other

Transaction value
Shares: -8,252
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,252
Exercise price: $27.94
Footnotes: F3, F6

SUPN transaction Derivative

Director Stock Option (Right to Buy)

Other

Transaction value
Shares: -7,296
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,296
Exercise price: $33.52
Footnotes: F3, F7

SUPN transaction Derivative

Director Stock Option (Right to Buy)

Other

Transaction value
Shares: -4,977
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,977
Exercise price: $50.20
Footnotes: F3, F8

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Frederick M. Hudson is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 8 footnotes

Footnote F1

Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. ("Indivior"), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals"), at the effective time of the merger on 11/2/26, Artemis Merger Sub Inc. merged with and into Supernus Pharmaceuticals, with Supernus Pharmaceuticals surviving as a wholly-owned subsidiary of Indivior. At the effective time, each outstanding share of Supernus Pharmaceuticals common stock was cancelled and automatically converted into the right to receive 1.5401 shares of Indivior common stock. In connection with the merger, Indivior changed its name to "Supernus, Inc." The reporting person's shares of Supernus Pharmaceuticals common stock were disposed of, and the shares of Supernus, Inc. common stock received in exchange were acquired, pursuant to the merger. The reporting person received no cash consideration other than cash in lieu of a fractional share.

Footnote F2

Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.

Footnote F3

Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. ("Indivior"), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals"), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.

Footnote F4

These restricted stock units will be settled in common stock upon vesting, which will occur on February 18, 2027.

Footnote F5

The option vests on February 23, 2024.

Footnote F6

The option vests on February 22, 2025.

Footnote F7

The option vests on February 19, 2026.

Footnote F8

Each option vests on February 18, 2027.